Compare iShares MSCI Australia ETF (EWA) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Revvity Inc — how do they compare? iShares MSCI Australia ETF trades at $29.88, while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals.
| EWA | RVTY | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $30.41 | $117.75 |
52-Week Low | $24.95 | $82.26 |
Market Cap | — | $12.91B |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA trades at $29.875, down 0.58% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with ADX readings above 40, indicating a trending market. Recent corporate actions include a dividend scheduled for June 2026. Key support and resistance cluster around $30, suggesting a critical price zone for near-term direction.
Outlook remains cautiously optimistic given technical strength, but fundamental data is unavailable for valuation assessment. Risks include reliance on Australian economic conditions and market volatility. Investors should await updated financials to gauge intrinsic value and growth prospects amid evolving macroeconomic factors.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
